Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
about
sameAs
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsDiagnosis and treatment of latent infection with Mycobacterium tuberculosisUpdates on the risk factors for latent tuberculosis reactivation and their managementsIncidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisEligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control.An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS.Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort studyQuantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.Tuberculosis and HIV infection: epidemiology, immunology, and treatment.New approaches in the diagnosis and treatment of latent tuberculosis infectionAdverse reactions to first-line antituberculosis drugs.Current integration of tuberculosis (TB) and HIV services in South Africa, 2011.Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection.Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort StudyConsidering the role of four months of rifampin in the treatment of latent tuberculosis infection.Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy.Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analysesAntituberculosis drugs and hepatotoxicity.Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities.Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy.A tuberculin screening and isoniazid preventive therapy program in an inner-city population.A lentiviral vector-based therapeutic vaccine encoding Ag85B-Rv3425 potently increases resistance to acute tuberculosis infection in mice.Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?Use of isoniazid for latent tuberculosis infection in a public health clinic.Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.Treatment of latent Mycobacterium tuberculosis infection in intravenous drug users co-infected with HIV
P2860
Q24650581-67A8F34B-090B-46F9-A697-BD026DAE6037Q27021614-F3BDCA1B-5E4F-48B9-AD62-CD545891EFBCQ28073158-7C48C3BB-4FBB-4656-A051-7B1D885F3404Q28207601-4EA3D30F-9CBD-4CE9-8200-814348B14629Q33692355-CBC7E492-9E6B-4815-A9E2-AE75FCBB67E3Q33982867-263F6C3F-9CEE-4E1B-8C05-AAEA216B0E7BQ34011244-D5969A57-25DA-4D03-9DEB-4DC498B4F0C1Q34312746-759737C6-D0AB-44B6-A15F-6DA1E286E2A4Q34351266-540B2E84-9DCA-49FA-BA7D-B4081D235602Q34394728-933FEE25-DDA7-4EF9-909A-91BD89E4F700Q34419185-2ABDCE68-7D37-423E-9BB5-173D47BAD6EAQ34497890-72DEF62E-4ED8-4BBF-B47C-E02071EF8BEBQ34613299-CDA664AB-C0BE-4A8F-96E3-C91B0F8C103FQ34998102-14944D7B-C4B1-4774-8A4A-68C3913ECC15Q35197248-F4560DA3-4FF3-4F41-AEC0-8C08CC57AE04Q35297467-78870EDD-ADD2-4A58-A03F-87770F9CD641Q35754209-4D2517FC-688F-4032-8CCB-84F219A58D46Q35766814-164906E2-3794-4C54-BD9C-ECAD09AC7D4CQ35857278-AAE6CF1F-3ABF-4372-8CB8-A538C4B27B2EQ35917465-C37F5DD0-9158-49B0-92F9-E46E080871D0Q36343641-04562BD5-6572-4A95-BC88-CCFE68E7215BQ36628708-DFA5CF50-DBEB-4BCD-96DA-66DD841D3AD2Q36877233-56A92423-96B2-45AE-B6AB-1EF12B748C8AQ37443290-BA7EBC1E-CF78-42A1-ABAB-CB5722EF56D9Q39226175-F788D590-0443-4489-A31E-1A48B675F0D9Q39483273-AFE0F43C-82C6-4FE9-A85A-5270C32BDD39Q41139635-5B7A8CE0-05FE-4EA6-B9B3-F6F7F3F661E0Q43774777-D079E0D6-E9D5-4FD3-889A-4599FCD15AABQ44225838-4DBCD65F-A6A8-47E9-96CF-DED628A9E17EQ44353708-9310041B-CEB3-4081-BA6A-CDF00E1A3984Q44440459-317785FD-A85F-4B8D-9620-1941E35BECF0Q44661519-C501680B-F866-4A93-959B-8FAB86E0C043Q53851250-D9667563-7863-49E6-8CAB-04DDD377FB48Q56762802-A7D62C55-A1C1-47BC-98DF-4FB89C5B3DEA
P2860
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
description
article publié dans la revue scientifique The Lancet
@fr
im März 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 1998
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Randomised trial of isoniazid ...... uberculosis in HIV-1 infection
@en
Randomised trial of isoniazid ...... uberculosis in HIV-1 infection
@nl
type
label
Randomised trial of isoniazid ...... uberculosis in HIV-1 infection
@en
Randomised trial of isoniazid ...... uberculosis in HIV-1 infection
@nl
prefLabel
Randomised trial of isoniazid ...... uberculosis in HIV-1 infection
@en
Randomised trial of isoniazid ...... uberculosis in HIV-1 infection
@nl
P2093
P1433
P1476
Randomised trial of isoniazid ...... uberculosis in HIV-1 infection
@en
P2093
J Atkinson
J Desormeaux
J S Coberly
N A Halsey
P Losikoff
P304
P356
10.1016/S0140-6736(97)06532-X
P407
P577
1998-03-01T00:00:00Z